Alkermes Executive and Leadership Team

Blair Jackson, the Chief Executive Officer, Elect at Alkermes, prepares to guide the company's strategic direction and operational execution. Jackson's impending leadership role involves overseeing the enterprise's global biopharmaceutical operations, focusing on the development and commercialization of innovative medicines for complex psychiatric and neurological disorders. This executive's mandate includes driving scientific advancement, ensuring robust clinical development pipelines, and enhancing specialized commercial infrastructure. The Chief Executive Officer, Elect is tasked with steering Alkermes' mission to address serious unmet medical needs in conditions like addiction, schizophrenia, and opioid dependence. Blair Jackson's focus will be on strengthening the company's neuroscience expertise and patient-inspired science approach. By preparing to lead Alkermes, Jackson will ensure continued progress in improving how chronic neurological and mental health conditions are managed globally.

James Sellers, the Chief Technology Officer at Alkermes, directs the company's technological strategy and infrastructure. Sellers oversees the development and implementation of advanced technology solutions that support Alkermes' biopharmaceutical research and commercialization efforts. This leadership role involves ensuring the integrity and scalability of data systems, managing cybersecurity protocols, and driving innovation in digital platforms essential for drug discovery and patient engagement. The Chief Technology Officer's focus extends to optimizing operational efficiency through technology, enabling the company to effectively pursue treatments for complex psychiatric and neurological disorders. Sellers's expertise ensures that Alkermes leverages cutting-edge technology to advance its mission of delivering innovative medicines for conditions such as addiction and schizophrenia. By architecting robust technological frameworks, James Sellers directly supports the company's pursuit of addressing serious unmet medical needs across central nervous system diseases.

Stephen Schiavo, the Senior Vice President and Chief Human Resources Officer at Alkermes, shapes the company's talent strategy and organizational development. Schiavo leads all human resources functions, including talent acquisition, employee relations, compensation and benefits, and learning and development. This executive's responsibilities are critical for fostering a high-performance culture that aligns with Alkermes' patient-inspired approach to developing innovative medicines. The Chief Human Resources Officer ensures that the organization attracts, retains, and develops the skilled workforce necessary to advance treatments for complex psychiatric and neurological disorders. Stephen Schiavo's strategic direction supports the company's global operations by cultivating an environment where scientific expertise and dedication to patient well-being thrive. By championing employee engagement and organizational effectiveness, Schiavo directly contributes to Alkermes' capacity to address serious unmet medical needs in central nervous system diseases.

David Gaffin, the Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc., directs the company's comprehensive legal and compliance strategies. Gaffin oversees all legal affairs, ensuring adherence to regulatory requirements and ethical standards across Alkermes' global operations. This critical role involves managing intellectual property, corporate governance, and risk mitigation to support the development and commercialization of innovative medicines for complex psychiatric and neurological disorders. The Chief Legal Officer and Chief Compliance Officer ensures that Alkermes operates with the highest integrity, safeguarding its reputation and facilitating its mission to address serious unmet medical needs. David Gaffin's leadership provides essential legal and compliance frameworks that enable the company to advance treatments for conditions such as schizophrenia and bipolar disorder. By maintaining robust compliance programs, Gaffin directly supports Alkermes' commitment to patient-inspired science and responsible business practices.